Binds Antigen Characterized By Name Or Molecular Weight (e.g., Cea, Nca, Cc Glycoprotein, Melanoma Gp 150 Antigen, Etc.) Patents (Class 530/388.85)
-
Patent number: 8337844Abstract: A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.Type: GrantFiled: March 28, 2012Date of Patent: December 25, 2012Assignee: Merck Patent GmbHInventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
-
Publication number: 20120315287Abstract: The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein.Type: ApplicationFiled: May 30, 2012Publication date: December 13, 2012Applicant: University of Washington Through Its Center For CommercializationInventor: Jennifer D. Wu
-
Patent number: 8329181Abstract: The present invention provides methods for treating a B-cell lymphoma in a human subject. The methods of the invention comprise administering to a subject in need thereof an antibody or antigen-binding fragment thereof that specifically binds human CD20. In certain embodiments, the methods of the invention are useful for treating non-Hodgkin's B-cell lymphoma.Type: GrantFiled: December 13, 2011Date of Patent: December 11, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
-
Publication number: 20120308478Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.Type: ApplicationFiled: November 11, 2010Publication date: December 6, 2012Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
-
Publication number: 20120308582Abstract: The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.Type: ApplicationFiled: May 31, 2012Publication date: December 6, 2012Applicant: NOVARTIS AGInventors: Larry Alexander GAITHER, Christopher John ROTHWELL
-
Patent number: 8324354Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.Type: GrantFiled: October 31, 2007Date of Patent: December 4, 2012Assignee: Stichting Dienst Landbouwkundig OnderzoekInventor: Hilda Elizabeth Smith
-
Patent number: 8323653Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.Type: GrantFiled: September 7, 2007Date of Patent: December 4, 2012Assignee: MedImmune, LLCInventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
-
Publication number: 20120301489Abstract: Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are disclosed. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an anti-Jagged antibody to a patient having a tumor or cancer.Type: ApplicationFiled: November 19, 2010Publication date: November 29, 2012Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Aaron Ken Sato, Alexandra Lazetic, Zhimin Ji
-
Publication number: 20120294865Abstract: The invention provides an integrin alpha-2 binding agent and methods of using an integrin alpha-2 binding agent to, e.g., inhibit proliferation of cancer cells, modulate tumor growth in a subject, inhibiting angiogenesis, or treating a fibrotic disorder. The invention further provides a method of producing an antibody, the method comprising propagating cancer cells in a 3-dimensional matrix; immunizing a mammal with the propagated cancer cells; and isolating an antibody from the immunized mammal. A method of identifying an agent that inhibits cancer cell proliferation also is provided.Type: ApplicationFiled: May 18, 2012Publication date: November 22, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Stephen J. Weiss, David T. Dudley
-
Patent number: 8298757Abstract: The present invention relates to a method for detecting an avian influenza virus by an immunological assay using an anti-influenza virus antibody being unreactive to human influenza type-A virus subtypes H1, H2 and H3 and a human influenza type-B virus and being reactive to plural subtypes of avian influenza viruses, and an immunochromatographic test tool for use in the method. According to the present invention, an avian influenza virus can be detected specifically, rapidly and in a simple manner, as distinguishing an avian influenza virus from a human influenza virus.Type: GrantFiled: August 31, 2007Date of Patent: October 30, 2012Assignees: Osaka Prefectural Government, Sysmex CorporationInventors: Kazuo Takahashi, Yoshinobu Okuno, Hiroshi Nishimura, Takeshi Imoarai, Noriyuki Saito, Tomokuni Taniguchi
-
Publication number: 20120264123Abstract: The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.Type: ApplicationFiled: June 1, 2012Publication date: October 18, 2012Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventors: Timothy J. O'Brien, Lowell J. Underwood, John Beard, Kazushi Shigemasa
-
Patent number: 8278424Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: April 26, 2011Date of Patent: October 2, 2012Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Patent number: 8278421Abstract: The present invention relates to materials and methods for human antibodies specific for the peptide hormone gastrin and uses of these antibodies in the treatment of subjects having cancer and other conditions or disorders related to gastrin expression.Type: GrantFiled: December 13, 2006Date of Patent: October 2, 2012Assignee: Xoma Techolology Ltd.Inventors: Linda Masat, Marina Roell
-
Patent number: 8273859Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.Type: GrantFiled: July 14, 2011Date of Patent: September 25, 2012Assignees: Perseus Proteomics Inc., The University of TokyoInventors: Hiroyuki Aburatani, Hiroko Iwanari, Isao Kohno
-
Patent number: 8258267Abstract: The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-IO, CXCL1O), thereby modulating the interaction between IP-IO and its receptor, CXCR3, and/or modulating the biological activities of IP-IO. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.Type: GrantFiled: February 28, 2008Date of Patent: September 4, 2012Assignee: NovImmune S.A.Inventors: Nicolas Fischer, Marie Kosco-Vilbois, Olivier Leger
-
Publication number: 20120219560Abstract: The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and/or a de-N-acetylated sialic acid-modified cell surface protein.Type: ApplicationFiled: February 24, 2012Publication date: August 30, 2012Inventors: GREGORY R. MOE, Charles Paul Plested
-
Publication number: 20120219569Abstract: The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or of inhibiting the development of primary tumours and/or of inhibiting its metastasis-promoting activity, which antibodies may consist of the antibodies TS151 and/or TS151r.Type: ApplicationFiled: April 16, 2012Publication date: August 30, 2012Applicant: PIERRE FABRE MEDICAMENTInventors: JEAN-FRANÇOIS HAEUW, LILIANE GOETSCH
-
Publication number: 20120207772Abstract: The present invention provides antibodies that simultaneously bind the ?- and ?-subunits of an intact MUC1 protein, and methods for making and using such antibodies.Type: ApplicationFiled: November 16, 2011Publication date: August 16, 2012Applicants: BIOMODIFYING, LLC, RAMOT AT TEL AVIV UNIVERSITY, LTD.Inventors: DANIEL B. RUBINSTEIN, DANIEL H. WRESCHNER
-
Patent number: 8227194Abstract: The invention relates to antibodies that bind to a fragment of the Response Gene to Complement-32 (RGC-32), as well as methods of using these antibodies. Particular methods of using the antibodies of the present invention include, but are not limited to, methods of detecting RGC-32 in a sample, methods of assaying cell proliferation, as well as methods of detecting and/or monitoring the progression of abnormal conditions in a subject, where the disease states are associated with the presence or absence of RGC-32.Type: GrantFiled: April 10, 2006Date of Patent: July 24, 2012Assignee: University of Maryland, BaltimoreInventors: Horea Rus, Tudor Constantin Badea, Matthew Fosbrink
-
Patent number: 8207311Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.Type: GrantFiled: May 17, 2004Date of Patent: June 26, 2012Assignee: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
-
Patent number: 8206711Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.Type: GrantFiled: December 2, 2009Date of Patent: June 26, 2012Assignees: Biogen Idec Inc., Genentech, Inc.Inventors: Christine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
-
Patent number: 8206932Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: March 27, 2009Date of Patent: June 26, 2012Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Pia M. Challita-Eid, Arthur B. Raitano
-
Patent number: 8192739Abstract: Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.Type: GrantFiled: June 5, 2009Date of Patent: June 5, 2012Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Ken Chang, Sailaja S. Vanama, Edmund A. Rossi
-
Patent number: 8187602Abstract: The present invention discloses anti-histone H1 monoclonal antibodies, hybridomas for the production thereof, and polypeptides, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation.Type: GrantFiled: April 19, 2010Date of Patent: May 29, 2012Assignee: Amateraspharma Inc.Inventors: Takeshi Goto, Shuji Sato, Kazuhisa Ono, Seiko Shigeta, Seiji Kawamoto, Shigeru Goto
-
Publication number: 20120129168Abstract: The present invention detects SNX5 in a sample from a subject. The SNX5 is used as a tumor marker specific to papillary thyroid carcinoma, whereby diagnosis of papillary thyroid carcinoma is carried out easily. The present invention provides also a technique of discriminating papillary thyroid carcinoma using the tumor marker.Type: ApplicationFiled: April 7, 2010Publication date: May 24, 2012Inventors: Shingo Ichimiya, Tomoki Kikuchi, Akiko Tonooka, Noriyuki Satoh
-
Publication number: 20120114672Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to Cadherin-17 with high affinity. Nucleic acid molecules encoding Cadherin-17 antibodies, expression vectors, host cells and methods for expressing the Cadherin-17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Cadherin-17 antibodies are also provided. Methods for detecting Cadherin-17, as well as methods for treating various cancers, including colorectal cancer, are disclosed.Type: ApplicationFiled: April 20, 2010Publication date: May 10, 2012Applicant: OXFORD BIOTHERAPEUTICS LTD.Inventors: Christian Rohlff, Jonathan Alexander Terrett
-
Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
Patent number: 8173781Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.Type: GrantFiled: June 30, 2009Date of Patent: May 8, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki -
Publication number: 20120100159Abstract: Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided.Type: ApplicationFiled: March 16, 2007Publication date: April 26, 2012Inventors: Wei-Ching Liang, Chie Sakanaka, Yan Wu
-
Publication number: 20120087931Abstract: Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are described. In particular, specific antibodies are provided, which are capable of binding an epitope of Hsp70 that is extracellularly localized on diseased tissue and cells, in particular on tumor cells and infected cells.Type: ApplicationFiled: April 6, 2011Publication date: April 12, 2012Inventor: Gabriele Multhoff
-
Patent number: 8153125Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).Type: GrantFiled: May 20, 2004Date of Patent: April 10, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Jeffry D. Watkins, Julian Davies, David M. Marquis, Barrett W Allan, Brian Ondek
-
Patent number: 8147832Abstract: A CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.Type: GrantFiled: August 13, 2004Date of Patent: April 3, 2012Assignee: Merck Patent GmbHInventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
-
Publication number: 20120070430Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.Type: ApplicationFiled: April 22, 2010Publication date: March 22, 2012Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
-
Publication number: 20120064600Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: ApplicationFiled: August 11, 2011Publication date: March 15, 2012Applicant: WYETH LLCInventors: Erwin R. BOGHAERT, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil R. Sreekumar
-
Publication number: 20120058131Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer treatment, and for drug development.Type: ApplicationFiled: January 21, 2010Publication date: March 8, 2012Applicant: OXFORD BIOTHERAPEUTICS LTDInventor: Christian Rohlff
-
Patent number: 8129129Abstract: The present invention describes a method for diagnosing tumors of the reproductive organs which is characterized by determination of the afamin content in a sample of a body fluid or in a tissue sample, wherein a tumor is diagnosed if the afamin content in the sample is decreased compared to the afamin content in a sample from a person without a tumor of the reproductive organs.Type: GrantFiled: March 12, 2010Date of Patent: March 6, 2012Assignee: Vitateq Biotechnology GmbHInventor: Hans Dieplinger
-
Publication number: 20120052076Abstract: The present invention teaches anti-Trop-2 monoclonal antibodies with high affinity and able to recognize different regions of the Trop-2 molecule, and uses thereof in the treatment and diagnosis of tumors, such as for example endometrium, breast, head and neck, colon-rectum, stomach, lung, ovary, prostate, pancreas, kidney, cervix and bladder (urothelial) tumors.Type: ApplicationFiled: February 5, 2009Publication date: March 1, 2012Inventor: Saverio Alberti
-
Patent number: 8124738Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.Type: GrantFiled: September 26, 2006Date of Patent: February 28, 2012Assignee: Medarex, Inc.Inventors: Jonathan Alexander Terret, Li-sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia
-
Publication number: 20120039807Abstract: The invention provides antibodies against the A2 domain of tenascin-C and methods of using the same.Type: ApplicationFiled: August 11, 2011Publication date: February 16, 2012Inventors: Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Publication number: 20120034168Abstract: An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases.Type: ApplicationFiled: April 22, 2009Publication date: February 9, 2012Applicants: Fondazione IRCCS "Istituto Nazionale dei Tumori", Universita' degli Studi di VeronaInventors: Marco Colombatti, Giulio Fracasso, Sara Cingarlini, Silvana Canevari, Mariangela Figini
-
Patent number: 8110195Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody binding to ganglioside GM2, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: June 18, 2010Date of Patent: February 7, 2012Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Motoo Yamasaki, Nobuo Hanai, Emi Hosaka, Kazuya Yamano
-
Patent number: 8101185Abstract: The present invention relates to a cell for the production of an anti-IL-5 antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: June 18, 2010Date of Patent: January 24, 2012Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Motoo Yamasaki, Nobuo Hanai, Emi Hosaka, Kazuya Yamano
-
Patent number: 8101179Abstract: A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in culture of the CD20 antigen expressing cells without effector cells. The anti-CD20 monoclonal antibody is incorporated into chimeric anti-CD20 monoclonal antibodies in which the amino acid sequences of the variable regions of the anti-CD20 monoclonal antibody and the amino acid sequences of the constant regions of human immunoglobulin are fused. Also a humanized anti-CD20 monoclonal antibody is described which includes all of the variable region CDRs of the H chain of the anti-CD20 monoclonal antibody and all of the variable region CDRs of the L chain of the anti-CD20 monoclonal antibody and an amino acid sequence of human immunoglobulin. A nucleotide sequence encoding the amino acid sequence of the chimeric or humanized anti-CD20 monoclonal antibody can be expressed in mammalian cells.Type: GrantFiled: March 31, 2006Date of Patent: January 24, 2012Assignee: Biomedics Inc.Inventors: Masanori Numazaki, Tetsuo Nakamura, Sadakazu Usuda, Eduardo A. Padlan
-
Patent number: 8101720Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.Type: GrantFiled: January 25, 2008Date of Patent: January 24, 2012Assignee: Xencor, Inc.Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
-
Publication number: 20120003157Abstract: The present invention relates to the use of anti-90K monoclonal antibodies for prevention and treatment of tumors and metastases thereof. In particular, the invention relates to the use of anti-90K monoclonal antibodies able to inhibit the adhesive processes of tumor cells and angiogenesis in tumors such as breast cancer, ovarian cancer, lung cancer, gastrointestinal cancer, melanoma, lymphoma and other tumors overexpressing 90K.Type: ApplicationFiled: February 18, 2010Publication date: January 5, 2012Inventor: Stefano Iacobelli
-
Patent number: 8088896Abstract: The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods for using the same. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: October 12, 2006Date of Patent: January 3, 2012Assignee: Morphosys AGInventors: Michael Tesar, Ute Jäger
-
Patent number: 8088357Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.Type: GrantFiled: December 1, 2003Date of Patent: January 3, 2012Assignee: Nemod Biotherapeutics GmbH & Co. KGInventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
-
Patent number: 8088378Abstract: The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: July 15, 2008Date of Patent: January 3, 2012Assignee: Genetech Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8071323Abstract: Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided.Type: GrantFiled: April 6, 2007Date of Patent: December 6, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu
-
Patent number: 8067001Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: June 24, 2010Date of Patent: November 29, 2011Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimishisa Ichikawa, Robert P. Kimberly, William J. Koopman
-
Patent number: 8062887Abstract: The present invention provides a monoclonal antibody recognizing modification after translation of p53 in a manner specific to a modification site, an antibody microarray comprising the antibody immobilized on a substrate, etc. Disclosed is a monoclonal antibody which reacts specifically with a peptide consisting of an amino acid sequence of at least 6 consecutive amino acids containing a predetermined amino acid residue of the amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid residue is phosphorylated or acetylated, or with a peptide having one to several arbitrary amino acids added to the above peptide, but does not react with the above peptide which is not phosphorylated or acetylated.Type: GrantFiled: March 31, 2006Date of Patent: November 22, 2011Assignees: National University Corporation, Hokkaido University, Genenet Co., Ltd.Inventors: Kazuyasu Sakaguchi, Yoshiro Chuman, Yasuo Akebiyama, Miho Matsukizono, Maki Watanabe, Junichi Tsutsumi